Biosig Technologies, Inc. (NASDAQ:BSGM) CEO Kenneth L. Londoner acquired 8,500 shares of the company’s stock in a transaction on Thursday, January 10th. The shares were bought at an average cost of $4.38 per share, with a total value of $37,230.00. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of BSGM traded down $0.02 during midday trading on Friday, hitting $4.21. 40,028 shares of the company traded hands, compared to its average volume of 22,212. Biosig Technologies, Inc. has a 52 week low of $3.21 and a 52 week high of $7.88.
BSGM has been the subject of several research reports. Zacks Investment Research raised shares of Biosig Technologies from a “sell” rating to a “hold” rating in a report on Wednesday, December 5th. Roth Capital initiated coverage on shares of Biosig Technologies in a report on Thursday, December 6th. They set a “buy” rating and a $14.00 price objective for the company.
About Biosig Technologies
BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.
Featured Article: What is net income?
Receive News & Ratings for Biosig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.